[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity--overweight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity--overweight":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,181,0,25,[9,41,75,99,127,151,172,196,227,252,293,315,342,367,402,435,456,488,514,540,560,590,618,646,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638169","phase-2-bariatric-endoscopic-antral-myotomy-combined-with-fundal-gastric-mucosal-ablation-100638169",false,"NCT07612527","Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation","Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation for The Management of Obesity","Inclusion Criteria:\n\nBody mass index (BMI) of ≥ 30 kg\u002Fm2 up to 40 kg\u002Fm2. BMI of 27.0 to 29.9 kg\u002Fm2 will be included on the condition of the presence of at least 1 obesity-related comorbidity (Indications based according to the American and European societies for bariatric endoscopy guidelines)\n\nExclusion Criteria:\n\n* Subjects with any previous surgeries to the stomach\n* Any previous bariatric procedures\n* Any current medications for the management of obesity (must be stopped at least 3 months before recruitment)\n* Evidence of severe gastritis, gastric peptic ulcer, or gastric cancer\n* Coagulopathy\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways. Accordingly, endoscopic gastric fundal mucosal ablation (GFMA) may benefit patients with obesity. Ablation not only affects these mechanisms, but similar to what happens after mucosal ablation for other indications (e.g. ESD for tumor removal), it is expected to cause shrinking of the fundus and reduce gastric volume.\n\nAnother potential target to achieve weight loss is gastric emptying. This is a critical step in digestion that has been found to be more rapid after prolonged exposure to a high-fat diet in both animal and human studies, with rapid emptying also being more common in young people with obesity in some studies. The bariatric endoscopic antral myotomy (BEAM) procedure has been shown to consistently delay gastric emptying without triggering symptoms of gastroparesis and to produce substantial weight loss.\n\nBoth GFMA and BEAM procedures have the advantages of being minimally invasive, performed completely endoscopic and less costly than surgical alternatives or other known endoscopic techniques like intragastric balloon or endoscopic sleeve gastroplasty.",[27,28],"Obesity & Overweight","Bariatric Endoscopy","RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":30,"type":33},{"date":36,"type":21},"2027-12",{"name":38,"class":39},"Cairo University","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100652893","phase-1-alpelisib-challenge-test-act-100652893","NCT07778524","Alpelisib Challenge Test (ACT)","Alpelisib Challenge Test (ACT) for Assessment of Pancreatic β-Cell Reserve, Pilot & Feasibility Study","Inclusion Criteria:\n\n* Adults aged 18-70 years\n* Able to understand wrifen and spoken English and\u002For Spanish\n* Body mass index of 18-45 kg\u002Fm2 (or 18-42 kg\u002Fm2 for those of Asian ancestry)\n\n  * For Lean group: BMI 18.0-24.9 kg\u002Fm2 (or 18.0-22.9 kg\u002Fm2 for those of Asian ancestry)\n  * For Overweight group: BMI 25.0-29.9 kg\u002Fm2 (or 23.0-27.4 kg\u002Fm2 for those of Asian ancestry)\n  * For Obesity group: BMI 30.0-45.0 kg\u002Fm2 (or 27.5-42 kg\u002Fm2 for those of Asian ancestry)\n\nExclusion Criteria:\n\n* Inability to provide informed consent in English or Spanish\n* Unwillingness to fast (except water) for up to 18 hours\n* Unwillingness not to get out of bed and to use bedpan\u002Furinal to void for up to 15 hours\n* Documented weight change of ≥ 5.0% of baseline within the previous 3 months\n* Abnormal blood pressure\n\n  * Systolic blood pressure \\\u003C 90 mm Hg or \\> 160 mm Hg, and\u002For\n  * Diastolic blood pressure \\\u003C 55 mm Hg or \\> 100 mm Hg\n* Abnormal resting heart rate \\\u003C 55 bpm or ≥ 110 bpm\n\n  * Sinus tachycardia that has been extensively worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion\n  * Sinus bradycardia between heart rates of 45 and 54 bpm may be permitted at the PI's discretion if in a clinically appropriate setting (e.g., toned athlete, taking beta blockers)\n* Abnormal (i.e., non-regular) heart rhythm detected on physical exam\n* Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant\n* Liver function abnormalities (either of the following)\n\n  * Transaminases (AST or ALT) \\> 3.0 x the upper limit of normal\n  * Total bilirubin \\> 1.25 x the upper limit of normal\n* Laboratory evidence of diabetes mellitus:\n\n  * Hemoglobin A1c ≥ 6.5%, and\u002For\n  * Fasting plasma glucose ≥ 126 mg dL-1\n* Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential\n* Women currently pregnant\n* Women currently breastfeeding\n* History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes):\n\n  * Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency\n  * Plasma glucose ≥ 126 mg\u002FdL after 8-h fast\n  * Plasma glucose of ≥ 200 mg\u002FdL at 2 h after ingestion of a 75-g glucose load\n  * Random plasma glucose ≥ 200 mg\u002FdL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state\n* History of gestational diabetes mellitus within the previous 5 years\n* Use of most antidiabetic medications within the 90 days prior to screening\n\n  * Exceptions: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin\n  * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening\n* Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)\n* Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)\n\n  * Atherosclerotic cardiovascular disease\n  * Stable or unstable angina\n  * Myocardial infarction\n  * Ischaemic or hemorrhagic stroke\n  * Peripheral arterial disease (claudication)\n  * Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor)\n  * History of percutaneous coronary intervention\n  * Congestive heart failure (NYHA Class ≥ 2)\n  * Severe valvular heart disease (e.g., aortic stenosis)\n  * Pulmonary hypertension\n* Advanced or severe liver disease, including but not limited to:\n\n  * Advanced liver fibrosis, as determined by non-invasive testing\n  * Cirrhosis of any etiology\n  * Autoimmune hepatitis or other rheumatologic disorder affecting the liver\n  * Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis)\n  * Chronic liver infection (e.g., viral hepatitis, parasitic infestation)\n  * Hepatocellular carcinoma\n  * Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease)\n* Psychiatric diseases causing functional impairment that:\n\n  * Are or have been decompensated within 1 year of screening, and\u002For\n  * Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain\u002Fmetabolic dysfunction (e.g., clozapine, olanzapine)\n* Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation\n* Bleeding disorders, including due to anticoagulation, or significant anemia (see above)\n* Active malignancy, or hormonally active benign neoplasm, except allowances for:\n\n  * Non-melanoma skin cancer\n  * Differentiated thyroid cancer (AJCC Stage I only)\n* Clinical concern for increased risk of volume overload, including due to medications and\u002For heart\u002Fliver\u002Fkidney problems, as listed above\n* Use of certain medications currently or within 30 days prior to screening:\n\n  * Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for:\n\n    * Use of drugs prescribed for indications other than the exclusionary diagnoses\u002Fpurposes listed above (e.g., ACEi\u002FARB used for uncomplicated hypertension rather than for congestive heart failure, etc.)\n    * Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded\n  * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted\n* History of certain weight-loss (bariatric) surgery, including:\n\n  * Roux-en-Y gastric bypass\n  * Biliopancreatic diversion\n  * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months\n* Clinical concern for alcohol overuse based on chart review and\u002For by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females\n* Regular tobacco use (smoking more than 1 cigarette per week) or regular nicotine vaping (daily)\n* Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening\n* History of or ongoing febrile illness within 14 days of screening\n* Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and\u002For interfere with the analysis of study data.\n* Known allergy\u002Fhypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy\u002Fhypersensitivity as judged by the investigator.\n* Concurrent enrollment in another clinical study of any investigational drug\u002Fbiologic therapy within 5 half-lives of an investigational agent or biologic.",true,"70 Years",{"count":51,"type":21},15,[53],"PHASE1","The goal of this study is to test a potentially easier method for measuring how much insulin a person is capable of producing than the current gold-standard method, the \"hyperglycemic clamp.\" Participants will come in for a two-day (overnight) visit in which they will first undergo a \"hyperglycemic clamp,\" in which they receive an intravenous (into the vein) infusion of glucose (sugar) in order to measure the maximum amount of insulin their body produces in response. They will then consume a series of three standardized meals throughout the rest of the day. At 23:00, they will take a single dose of alpelisib, a drug that interferes within insulin's actions in the body. Then, the following morning, they will undergo a \"Mixed Meal Tolerance Test\" in which they consume a standardized liquid nutritional beverage and have blood drawn periodically before and during the test.",[56,57,27,58],"Insulin Resistance","Type 2 Diabetes","Healthy Adult Participants",[60,61,62,63,64,65],"Insulin resistance","Type 2 diabetes","Hyperinsulinemia","Obesity","Overweight","Healthy volunteers","NOT_YET_RECRUITING","2026-08-18",{"date":32,"type":33},{"date":70,"type":21},"2026-09-01",{"date":72,"type":21},"2028-08-31",{"name":74,"class":39},"Columbia University",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100652161","effect-of-glp-1-receptor-agonists-on-periodontal-health-and-response-to-nonsurgical-periodontal-therapy-100652161","NCT07770906","Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy","Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Periodontal Health and Response to Non-Surgical Periodontal Therapy","GLP1-PERIO","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Body mass index (BMI) ≥25 kg\u002Fm²\n* Presence of at least 20 functional teeth\n* Diagnosis of periodontitis\n* For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months\n\nExclusion Criteria:\n\n* Age between 18 and 65 years\n* Body mass index (BMI) ≥25 kg\u002Fm²\n* Presence of at least 20 functional teeth\n* Diagnosis of periodontitis\n* For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months",{"count":84,"type":21},40,[86],"NA","This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.\n\nParticipants with obesity and periodontitis will be divided into two groups: those who have been using a GLP-1 RA for at least 3 months and those who are not using any medication for obesity. All participants will receive the same non-surgical periodontal treatment, including oral hygiene instruction, scaling, and root planing.\n\nPeriodontal clinical measurements and gingival crevicular fluid samples will be collected before treatment and at 3 and 6 months after treatment. The study will compare changes in periodontal health and inflammatory markers between the two groups to determine whether GLP-1 RA use is associated with periodontal health and the response to non-surgical periodontal therapy.",[89,27],"Periodontal Disease",[91,92],"PERIODONTAL DISEASE","OBESİTY",{"date":30,"type":33},{"date":70,"type":21},{"date":96,"type":21},"2027-12-01",{"name":98,"class":39},"Cukurova University",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":48,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":126},"100643653","shift-workers-health-behavior-action-program-across-europe-100643653","NCT07631767","Shift Workers' Health Behavior Action Program Across Europe","SHAPE","Inclusion Criteria:\n\n* Age ≥ 21 years\n* Work ≥ 24 hours per week\n* Shift work duration \\> 3 years and currently doing night shifts\n* Expected to continue night shiftwork for at least 1 year after inclusion\n* On average working ≥ 4 night shifts per month\n* Working generally ≥ 2 consecutive night shifts\n* In possession of a smartphone and willing to download the study application\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Pregnant or lactating\n* Chronic diseases with ongoing therapy (e.g. renal failure, active hepatitis, cirrhosis, myocardial infarction, chronic obstructive pulmonary disease and cancer)\n* Current or recent use of medications interfering with sleep, including: Central nervous system stimulants (e.g., Ritalin, Adderall, Modafinil or similar); Chronic use of sleep agents (e.g., benzodiazepine, non-hypnotic benzodiaze-pine, first-generation antihistamine, melatonin receptors agonists or similar); Other medications or combinations significantly affecting sleeping patterns\n* Recent or ongoing psychotherapy for sleep disorders\n* Current or recent use of medications affecting appetite or weight regulation, including: Appetite-enhancing\u002Fweight-gain medications (e.g., atypical antipsychotics, cor-ticosteroids such as prednisone, mirtazapine or similar); Appetite-suppressing\u002Fweight-loss medications (e.g., CNS stimulants such as Ritalin, Adderall, GLP-1 receptors agonists or similar); Other medications or combinations significantly influencing appetite or body weight\n* Participation in another human trial, lifestyle program or weight loss intervention within the past 3 months\n* Planned surgical procedure during the study period\n* History of or planned bariatric surgery\u002Ftreatment","21 Years",{"count":108,"type":21},400,[86],"This study evaluates the effects of a Combined Lifestyle Intervention Program (CLIP) on sleep, lifestyle behaviors, obesity risk and health in night-shift workers. The primary objective is to assess the effect of the CLIP on objectively measured sleep duration. Secondary objectives include behavioral outcomes related to sleep, diet, physical activity, and stress, as well as body weight and metabolic outcomes, . It is hypothesized that CLIP participants will show a greater increase in sleep duration than controls, alongside favorable changes in lifestyle and health outcomes.",[112,27,113],"Night Shift Work","Circadian Misalignment",[115,116,117,118,119],"Lifestyle","Stress","Sleep","Diet","Physical Activity",{"date":30,"type":33},{"date":122,"type":33},"2026-05-15",{"date":96,"type":21},{"name":125,"class":39},"Wageningen University",5,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100652611","redefining-evaluation-of-adiposity-and-leanness-broadening-objective-diagnostics-for-obesity-100652611","NCT07776678","Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity","Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity (REAL-BODY)","REAL-BODY","Inclusion Criteria:\n\n* Being willing to provide written informed consent prior to participation Being willing to complete the study visits and comply with the study procedures\n* Being willing to travel to the various study locations for On-site, DXA, MRI, and Phlebotomy visits\n* Being willing to change into appropriate form-fitting clothing for 3DO assessments and\u002For appropriate gowns for DXA and MRI imaging\n* Must have a BMI within the range of 18.5 - 45 kg\u002Fm2\n* Being willing to refrain from all food, drink, and substances for 8 hours prior to the On-site visit(s) and phlebotomy visit\n* Being willing to refrain from all food, drink, and substances for 4 hours prior to the DXA and MRI scan visits\n* Being willing to refrain from any exercise or vigorous physical activity for 24 hours prior to all visits\n* Stable weight (no more than 5 kg change) for 3 months prior to screening\n* If recruited in the Phoenix, AZ area, participants must be willing to drive yourself to the Phoenix Office location for the On-site Visits 1 and 2 (if applicable) located at the Exponent Phoenix Office.\n\nExclusion Criteria:\n\n* Being pregnant or attempting to become pregnant\n* Having medical implants, such as a pacemaker or metal joint replacements, or other metal implants contraindicated for MRI\n* Cosmetic implants, such as breast implants\n* Having a height greater than DXA scanning limit (77 inches)\n* Having a body weight greater than indicated for the equipment (400 lbs)\n* Prior amputation or major body-altering surgery that could invalidate body composition estimates\n* Having claustrophobia or a history of claustrophobia\n* Known HIV infection\n* Known Lipodystrophy\n* Known hydration abnormality (e.g., significant edema, end-stage renal disease, end-stage liver disease)\n* Severe illness or life-threatening conditions such as end-stage kidney, liver, lung disease, NYHA III-IV heart failure, or active malignancy",{"count":136,"type":21},300,"OBSERVATIONAL","The purpose of this study is to evaluate body composition across a variety of medical, professional, and commercial devices, including: bioelectrical impedance analysis (BIA) devices, 3-dimensional optical imaging (3DO), manual anthropometry measurements, dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and blood tests. The secondary study purpose is to compare body composition measurements from BIA devices, 3DO, and manual anthropometry measurements within a 1-week period for a subset of the study population.\n\nThe study plans to enroll 300 healthy (having no life-threatening conditions or diseases; male and female) participants, 18 years of age or older.",[27],[141],"Body Composition","2026-08-17",{"date":30,"type":33},{"date":145,"type":33},"2026-06-29",{"date":147,"type":21},"2027-03-30",{"name":149,"class":39},"Foundation for the National Institutes of Health",3,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":40},"100633430","comparing-the-effects-of-front-of-package-labeling-schemes-in-indonesia-100633430","NCT07526584","Comparing the Effects of Front-of-Package Labeling Schemes in Indonesia","Comparing the Effects of Two Front-of-Package Labeling Schemes Among Indonesian Consumers","Inclusion Criteria:\n\n* 18 years of age or older\n* Lives in Indonesia\n* Able to read and write in Indonesian\n* Has purchased processed foods in the last month\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Does not live in Indonesia\n* Not able to read and write in Indonesian\n* Has not purchased processed foods in the last month",{"count":159,"type":21},1000,[86],"The goal of this study is to examine what type of front-of-package label (FOPL) would be most effective at discouraging consumption of products high in nutrients of concern in Indonesia. The main questions this experiment aims to answer are:\n\n1. Would nutrient warning labels be more effective at discouraging consumption of products high in nutrients of concern compared to the Nutri-Level label?\n2. Would nutrient warning labels improve consumers' ability to identify unhealthy products compared to the Nutri-Level label?\n\nAdditionally, this experiment also aims to determine how should nutrient warning labels be designed to most effectively discourage consumption of products high in nutrients of concern among Indonesian consumers.",[163,27],"Nutrition","2026-08-14",{"date":67,"type":33},{"date":167,"type":33},"2026-08-01",{"date":169,"type":21},"2026-08",{"name":171,"class":39},"University of North Carolina, Chapel Hill",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":40},"100652203","motivational-interviews-based-on-the-five-step-5a-model-on-obesity-risk-100652203","NCT07769736","Motivational Interviews Based on the Five-Step (5A) Model on Obesity Risk","The Effect of Structured Motivational Interviews Based on the Five-Step (5A) Model on Behavioral Change in Individuals at High Risk of Obesity in Family Medicine: A Mixed-Methods Randomized Controlled Trial Study Protocol","Inclusion Criteria:\n\n* Aged:18-64 years,\n* Body Mass Index (BMI): 25.0-35.0 kg\u002Fm² (Overweight or Class I Obesity)\n* Literate,\n* Voluntary agreement to participate.\n\nExclusion Criteria:\n\n* Body Mass Index (BMI): \\>35.0 kg\u002Fm²,\n* Active involvement in a concurrent weight loss program,\n* Current use of anti-obesity medication,\n* Severe psychiatric or cognitive disorders,\n* Pregnancy,\n* Missing more than one motivational interview session,\n* Orthopedic conditions precluding physical activity.","64 Years",{"count":181,"type":21},60,[86],"The goal of this clinical trial is to learn if a structured motivational interviewing program based on the Five-Step (5A) model works to promote healthy lifestyle behaviors in individuals at high risk of obesity. It will also learn about the effects on anthropometric measurements and physical activity levels. The main questions it aims to answer are:\n\n* Does this structured program promote healthy lifestyle behaviors in individuals at high risk of obesity?\n* To what extent does it increase participants' intrinsic motivation and readiness for behavioral change?\n\nParticipants will:\n\n* Attend structured interview sessions throughout the designated process\n* Visit the clinic at regular intervals for follow-up and evaluations\n* Record their lifestyle changes, physical activity levels, and experiences throughout the process",[27],[63,186,187],"Motivational Interviewing","Behavior Change","2026-08-12",{"date":67,"type":33},{"date":191,"type":21},"2026-09",{"date":193,"type":21},"2026-11",{"name":195,"class":39},"Istinye University",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100651139","polydextrose-functional-gummies-for-weight-management-in-adults-with-overweight-or-obesity-100651139","NCT07758387","Polydextrose Functional Gummies for Weight Management in Adults With Overweight or Obesity","Randomized Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Functional Gummies With Polydextrose Versus Placebo for Weight Control in Adults With Overweight or Obesity","DEXTRO-PESO","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Body mass index (BMI) between 25 and 39.9 kg\u002Fm² (overweight or obesity class I-II).\n* Stable body weight (no change greater than 3%) in the 3 months before joining the study.\n* Usually eat at least 2 meals per day.\n* Able and willing to follow the study procedures for 24 weeks, attend all scheduled visits, and complete the required records.\n* Willing and able to sign the informed consent form.\n\nExclusion Criteria:\n\n* Type 2 diabetes with glycated hemoglobin (HbA1c) greater than 7%, type 1 diabetes, or type 2 diabetes treated with multiple daily insulin injections.\n* Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors for diabetes, heart failure, or chronic kidney disease.\n* Uncontrolled thyroid disease \\[thyroid-stimulating hormone (TSH) outside the normal range\\] or recent changes in thyroid medication in the last 3 months.\n* Significant gastrointestinal disease (such as severe irritable bowel syndrome, Crohn's disease, or ulcerative colitis).\n* History of bariatric surgery.\n* Liver cirrhosis.\n* Advanced chronic kidney disease (stage IV-V).\n* Following a very low-calorie diet (less than 800 kcal\u002Fday).\n* Alcohol dependence or heavy alcohol use that, in the investigator's opinion, could affect the study.\n* Current or recent eating disorder.\n* Planning to start or recently started a specific weight-loss diet different from the one recommended by the study endocrinology service.\n* Currently taking or having taken in the last 3 months medicines that affect appetite or body weight (such as anorectic drugs, GLP-1 receptor agonists, chronic corticosteroids, antipsychotics, or fiber supplements).\n* Pregnancy or breastfeeding.\n* Women of childbearing potential who are trying to become pregnant or plan to become pregnant during the study.\n* Known allergy or intolerance to any ingredient of the study gummies.\n* History of severe gastrointestinal problems with fermentable fibers.",{"count":205,"type":21},96,[86],"Overweight and obesity are common conditions that increase the risk of metabolic and cardiovascular diseases. Polydextrose is a type of dietary fiber that may help increase feelings of fullness by influencing natural hormones involved in appetite regulation. It may also improve postprandial glycemic responses and modulate the gut microbiota. However, evidence for its effectiveness in weight management remains limited.\n\nThe purpose of this study is to evaluate the efficacy and safety of functional gummies containing polydextrose compared with placebo for weight management in adults with overweight or obesity. Participants will be randomly assigned to receive either polydextrose or placebo gummies for 24 weeks, together with standardized dietary and physical activity recommendations.\n\nThe primary objective is to compare the percentage change in body weight over 24 weeks between participants receiving polydextrose gummies and those receiving placebo. The study will also evaluate appetite and satiety, body composition, waist circumference, metabolic parameters, quality of life, gastrointestinal symptoms, and the safety and tolerability of the study product.\n\nThe study hypothesis is that daily intake of polydextrose gummies for 24 weeks will lead to a greater reduction in body weight than placebo and may improve subjective feelings of appetite and satiety in adults with overweight or obesity.",[27],[210,211,212,64,63,213,214,215,216,141,217,218],"Polydextrose","Dietary Fiber","Functional Gummies","Weight Management","Weight Loss","Satiety","Appetite","Placebo-Controlled Trial","Randomized Clinical Trial",{"date":164,"type":33},{"date":221,"type":21},"2026-10-19",{"date":223,"type":21},"2027-10-29",{"name":225,"class":226},"Nutris We Care About You S.L.","INDUSTRY",{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":40},"100651067","glp-1s-in-hip-and-knee-arthroplasty-100651067","NCT07755085","GLP-1s in Hip and Knee Arthroplasty","Does the Preoperative Use of GLP-1 Agonists Change Outcomes in Patients Waiting for Total Hip and Knee Arthroplasty: A Pilot Randomized Control Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon\n* Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+\n* Patients must be between 18-90 years of age\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment that precludes study participation and compliance\n* Patients unwilling to undergo smoking cessation prior to surgery\n* Patients currently taking biologic medications that suppress the immune system\n* Patients currently taking GLP-1 medications\n* Patients with a contraindication to GLP-1 medication","90 Years",{"count":236,"type":21},100,[238],"PHASE4","The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.",[241,27,242],"Arthritis","GLP - 1","2026-08-07",{"date":245,"type":33},"2026-08-10",{"date":247,"type":21},"2026-10-01",{"date":249,"type":21},"2028-12",{"name":251,"class":39},"Nova Scotia Health Authority",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":260,"minAge":261,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":277,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":289,"leadSponsor":291,"locationsCount":40},"100648817","prebiotic-inulin-for-late-reproductive-individuals-100648817","NCT07724522","Prebiotic Inulin for Late-Reproductive Individuals","A Placebo Randomized Cross-Over Controlled Trial of Inulin Supplementation to Improve Cardiometabolic, Gut, and Vaginal Microbiome in Perimenopausal Women","PILI","Inclusion Criteria:\n\n* Body mass index: 25 - 40 kg\u002Fm2;\n* Menstrual cycle irregularity (cycle length outside 21 - 35 days or variation \\> 7 days) or\u002Fand ≥ 2 skipped cycles and interval of ≥ 60 days of amenorrhea; with or without hot flashes or\u002Fand night sweats;\n* Weight stable within the last 3 months (body weight fluctuations within the 5% of their habitual body weight);\n* Spending ≥ 6 hours sitting;\n* \\\u003C 150 minutes per week (50 minutes per day, 3 days per week OR 30 minutes per day, 5 days per week) of moderate to vigorous structured physical activity (i.e., planned intentional physical activity, not incidental movement).\n\nExclusion Criteria:\n\n* Recent antibiotic use oral or vaginal (≥ 6months);\n* Diagnosed with any chronic disease (e.g., any gastrointestinal condition like IBD, type 2 diabetes, or cancer);\n* Prescription of hormone replacement therapy, hormonal contraceptives, probiotics, GLP-1 medications, or weight loss medications\n* Smoking;\n* Recent blood donation (within the past 8-12 weeks);\n* Significant weight changes (≥5%) in the last 4 weeks;\n* Use of dietary supplements (unless discontinued 4 weeks prior);\n* Participants taking long-term, stable medications for chronic conditions such as hypertension or hyperlipidemia will not be excluded if their medication regimen has been unchanged for at least 2 years, as these treatments are part of their usual health status. Recent medication changes (within the past 6 months), initiation of new prescriptions, or use of medications known to affect metabolic, vascular, vaginal, hormonal, or gastrointestinal function will result in exclusion.\n* Fructose intolerance.","FEMALE","40 Years","55 Years",{"count":264,"type":21},27,[86],"This study aims to evaluate the effects of 2 weeks of inulin supplementation in perimenopausal women with overweight or obesity. The primary questions this study seeks to answer are:\n\n1. Does 2 weeks of inulin supplementation alter the gut and vaginal estrobolome compared with placebo?\n2. Does 2 weeks of inulin supplementation affect cardiovascular health compared with placebo?\n3. Does 2 weeks of inulin supplementation affect skeletal muscle health compared with placebo?\n\nResearchers will compare inulin with a placebo (a similar-looking supplement that does not contain inulin) to determine whether inulin influences gut and vaginal microbial function, cardiovascular health, and skeletal muscle health during the perimenopausal transition.\n\nParticipants will:\n\n* Take either inulin or a placebo for 2 weeks, followed by a 2- to 4-week washout period, and then switch to the other supplement for an additional 2 weeks.\n* Attend 8 study visits over approximately 12 to 16 weeks for assessments and sample collection.\n* Complete weekly phone calls to monitor symptoms, supplement adherence, and dietary intake.\n* Wear a Fitbit device throughout the study to monitor physical activity.",[27,268,269,270,271,272,273,274,211,275,276,56],"Perimenopausal Women","Prebiotics","Inulin","Muscle, Skeletal","Cardiovascular Diseases (CVD)","Microbiota","Gastrointestinal Microbiome","Women Health","Vascular Health",[278,163,279,64,63,280,281,282,283,284,285,270,276],"Perimenopause","Menopause transition","Cardiometabolic Health","Vascular function","Randomized Controlled Trial","Gut microbiome","Vaginal microbiome","Supplements",{"date":287,"type":33},"2026-08-11",{"date":167,"type":33},{"date":290,"type":21},"2028-02",{"name":292,"class":39},"George Washington University",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":300,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100650923","evaluating-the-efficacy-and-safety-of-lum-201-plus-semaglutide-versus-semaglutide-plus-placebo-in-older-obese-adults-100650923","NCT07754045","Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults","Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity","Inclusion Criteria:\n\n* Be willing to provide written informed consent to participate in this study.\n* Males or females, aged ≥ 60 to \\\u003C 85 years.\n* Have a BMI ≥ 30 kg\u002Fm2.\n* SPPB score at the screening visit ≥ 7 to ≤ 9.\n* Have a history of ≥ 1 self-reported unsuccessful dietary effort to lose weight.\n* Female participants must be postmenopausal, confirmed by an follicle stimulating hormone (FSH) level ≥ 25 IU\u002FL.\n* Male participants must be able to comply with contraception requirements.\n* Must agree to refrain from any reconstructive and\u002For cosmetic surgery and\u002For non-invasive cosmetic procedure that may affect body weight during the study such as mammoplasty, lipoplasty, non-invasive adipose and\u002For cellulite treatment devices.\n* Must refrain from scheduling any elective surgery and\u002For other invasive or non-invasive procedures during the study unless medically warranted.\n\nExclusion Criteria:\n\n* Have Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM).\n* Have laboratory evidence diagnostic of diabetes mellitus during screening.\n* Have history of diabetic ketoacidosis or hyperosmolar state\u002Fcoma within 6 months prior to screening.\n* Have a history of severe hypoglycemia.\n* Have a BMI \\> 45 kg\u002Fm2 or weight \\> 159 kg (350 lbs.).\n* Have a self-reported change in body weight \\> 5 kg (11 lbs.) within 3 months prior to screening.\n* Have received prior exposure to a GLP-1 receptor agonist (including dual GLP-1\u002F GIP receptor agonists\\]) within 180 days before screening, any other anti-obesity medication, glucose-lowering agent (non-GLP-1), or glucose lowering supplements such as berberine, etc. within 90 days before screening.\n* Have any other condition not listed in this section (for example, hypersensitivity or intolerance) that is a contraindication to GLP-1 receptor agonist or dual GLP-1\u002FGIP receptor agonist.\n* Have serum calcitonin concentration \\> 35 pg\u002FmL at screening.\n* Have a history of prior or planned surgical treatment for obesity.\n* Have uncontrolled hypertension with systolic blood pressure (SBP) ≥ 150 mm Hg and\u002For diastolic blood pressure (DBP) ≥ 95 mm Hg.\n* Mean QTcF (Fridericia \\[QTcF=QT\u002FRR1\u002F3\\]) interval \\> 450 ms (male) or \\> 470 ms (female) on triplicate ECGs.\n* Have fasting triglyceride \\> 500 mg\u002FdL.\n* Have any of the following within last 6 months prior to screening: NYHA Functional Classification I-IV heart failure, myocardial infarction, angina, coronary artery bypass graft, percutaneous coronary intervention, transient ischemic attack, stroke, or decompensated congestive heart failure.\n* Have an estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2.\n* Have a known clinically significant gastric emptying abnormality.\n* Have a history of chronic or acute pancreatitis, or severe gastroesophageal reflux disease and symptomatic cholelithiasis with intact gallbladder.\n* Have serum lipase and\u002For amylase above 1.5 × the upper limit of normal (ULN).\n* Have a history of hepatic disorders including cirrhosis or other hepatic disorder other than metabolic-associated fatty liver disease (MAFLD), or nonalcoholic fatty liver disease.\n* Have active hepatitis B or C virus at screening. Have known positive history of human immunodeficiency virus. Have an active Coronavirus Disease 2019 at screening.\n* Have an impaired liver function, defined as screening aspartate aminotransferase (AST) \\> 2.5 × ULN, or alanine aminotransferase \\> 2.5 × ULN, or total bilirubin level \\> 1.2 × ULN (except for cases of known Gilbert's Syndrome).\n* Alkaline phosphatase (ALP) level \\> 1.5 × ULN.\n* Have untreated or uncontrolled hypothyroidism or hyperthyroidism.\n* Have obesity induced by other endocrinologic disorders.\n* Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within the last 2 years.\n* Have any lifetime history of a suicide attempt.\n* Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within the past 5 years prior to screening.\n* Have had a transplanted organ (corneal transplants \\[keratoplasty\\] allowed) or awaiting an organ transplant.\n* Have any hematological condition that may interfere with HbA1c measurement (for example, hemolytic anemias, sickle cell disease).\n* Are receiving or have received within 3 months prior to screening chronic (\\> 2 weeks or 14 days) systemic glucocorticoid therapy or have evidence of a significant active autoimmune abnormality that has required treatment within the last 3 months.\n* Have current or recent treatment with medications and\u002For supplements that may cause significant weight gain.\n* Currently receiving or planning to initiate during the study any muscle toning or body contouring treatments such as high-intensity focused electromagnetic therapy, or neurotoxin injections targeting large muscle groups (for example, trapezius, gastrocnemius) for slimming or relaxation purposes.\n* Have taken within 3 months prior to randomization, medications (prescribed or over-the counter) or alternative remedies intended to promote weight loss.\n* Have started implantable or injectable contraceptives (such as Depo-Provera®) within 6 months prior to screening.\n* Documented moderate to severe obstructive sleep apnea (unless controlled by medically prescribed intervention for at least 3 months prior to screening).\n* Prior treatment with growth factors including, but not limited to, GH, IGF-1, and GH secretagogues.","60 Years","84 Years",{"count":303,"type":21},202,[24],"This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg\u002Fm\\^2, between the ages of 60 and 85 years that have mild functional impairment.",[27],"2026-08-06",{"date":245,"type":33},{"date":310,"type":21},"2027-02-15",{"date":312,"type":21},"2028-02-15",{"name":314,"class":226},"Lumos Pharma",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":48,"sex":260,"minAge":323,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":40},"100619937","improving-cervical-cancer-prevention-among-women-living-with-chronic-conditions-100619937","NCT07351110","Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.","Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions. Aim 3: Assess the Feasibility and Acceptability of the PINPOINT Intervention.","PINPOINT","Inclusion Criteria:\n\nThe following eligibility criteria will be used to determine inclusion into the study:\n\n1. Using the American Cancer Society (ACS) screening recommendations, adults aged over the age of 25 will be eligible\n2. Active UF Internal Medicine patient and has had an appointment in the last 2 months.\n3. Assigned sex at birth is female\n4. Have Obesity or Type 2 Diabetes\n5. Not currently pregnant (self-report)\n6. Have not given birth in the prior 12 weeks\n7. No previous history of cervical cancer\n8. No previous history of a hysterectomy\n9. Have not undergone cancer screening in the past 3 years or more\n10. Reside in the UFHCI Catchment Area (Alachua, Baker, Bradford, Citrus, Clay, Columbia, Dixie, Gadsden, Gilchrist, Hamilton, Jefferson, Lafayette, Lake, Leon, Levy, Madison, Marion, Putnam, Sumter, Suwannee, Taylor, UnioF1n, or Wakulla County).\n11. Have a mobile phone or access to a mobile phone that can be used to receive messages, or a valid email address.\n12. Are not currently scheduled to receive cervical cancer screening via clinician sampling (pap smear).\n\nExclusion Criteria:\n\n* Previous history of cervical cancer\n* Total hysterectomy\n* Pregnant","25 Years",{"count":325,"type":21},20,[86],"Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PINPOINT intervention among patients with high-risk profiles for cervical cancer who do not meet the recommended screening for cervical cancer.",[329,330,27],"Diabetes","Cervical Cancer (Early Detection)",[332,333,334],"cervical cancer screening","self-collection","self-sampling",{"date":245,"type":33},{"date":337,"type":21},"2026-08-30",{"date":339,"type":21},"2028-03-31",{"name":341,"class":39},"University of Florida",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":40},"100614138","waiting-on-atrial-fibrillation-intervention-therapy-wait-study-100614138","NCT07275697","Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study","WAIT","Inclusion Criteria:\n\nTo be included in the trial, subjects must meet all of the following criteria:\n\n1. Provision of written informed consent prior to participation.\n2. Age ≥18 years.\n3. Scheduled for first-time catheter ablation for atrial fibrillation using a pulmonary vein isolation (PVI) technique.\n4. Body Mass Index (BMI) ≥30 kg\u002Fm² (obesity) OR\n\n   BMI ≥27 kg\u002Fm² (overweight) with one or more of the following comorbidities:\n   * prediabetes (defined as HbA1c 39-47 mmol\u002Fmol or fasting glucose 5,6-6,9 mmol\u002FL),\n   * known diabetes type 2\n   * known hypertension (prior diagnosis and\u002For treatment with antihypertensive medication)\n   * new diagnosis of hypertension (according to ESC GL for hypertension: Systolic BP ≥140 mmHg and\u002For diastolic BP ≥ 90 mmHg based on two readings on two separate visits, OR Ambulatory BP monitoring (24h average) ≥ 130\u002F80 mmHg)\n   * dyslipidemia defined as either one of the following\n\n     * Known diagnosis of hyperlipidemia or\n     * Treatment with lipid lowering medication\n\n   OR either of the following:\n   * LDL \\> 3.0 mmol\u002Fl\n   * Total cholesterol \\> 5 mmol\u002Fl\n   * Triglycerides \\> 1.7 mmol\u002Fl\n   * HDL (\\\u003C 1 mmol\u002Fl if male, \\\u003C 1.2 mmol\u002Fl if female) AND\u002FOR\n\n     * atherosclerotic cardiovascular disease (prior myocardial infarction (MI), stroke, or peripheral arterial disease with claudication and ankle-brachial index \\\u003C0.85, prior revascularization, or amputation)\n     * obstructive sleep apnea.\n5. For women of childbearing potential: Inclusion after a highly sensitive negative pregnancy test and agreement to use highly effective contraception during the study period (e.g., hormonal contraception, intrauterine device, or barrier method combined with spermicide).\n\nExclusion Criteria:\n\n* Morbid obesity (BMI \\>40 kg\u002Fm²).\n* Current use of GLP-1 receptor agonist therapy or dual agonist therapy within 6 months before screening.\n* Current use of DPP-IV inhibitors.\n* Diabetes type 1\n* Known intolerance or contraindication to semaglutide.\n* History of pancreatitis or recurrent hypoglycemia.\n* Uncontrolled diabetic retinopathy\n* Severe renal failure (estimated glomerular filtration rate \\[eGFR\\] \\\u003C15 mL\u002Fmin\u002F1.73 m² or in dialysis)\n* Severe hepatic failure (decompensated liver disease Child-Pugh class C)\n* Severe cardiac failure (NYHA class IV)\n* Life expectancy \\\u003C12 months.\n* Inability to self-administer the investigational medicinal product.\n* Prior catheter ablation procedure for atrial fibrillation.\n* Pregnancy, breastfeeding, or planned pregnancy during or within two months after the study period.\n* Participation in another interventional clinical trial within the past 30 days.",{"count":350,"type":21},200,[238],"Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with symptoms, reduced quality of life, heart failure, stroke, and a high risk of recurrence after catheter ablation. Many patients scheduled for their first ablation are overweight or have obesity, which is one of the strongest predictors of AF recurrence. Weight loss and risk-factor management are known to improve the outcome of ablation, but lifestyle changes are often difficult to achieve in routine care.\n\nSemaglutide (Wegovy®) is a GLP-1 receptor agonist approved in the EU for weight management. It has been shown to produce substantial and sustained weight loss and to improve metabolic and cardiovascular risk factors. Whether treatment with semaglutide before AF ablation can improve long-term rhythm outcomes has never been tested in a randomized clinical trial.\n\nThe WAIT-AF study is a randomized, open-label trial with blinded endpoint assessment. The study includes adults with AF who are scheduled for their first catheter ablation and have a BMI ≥30 kg\u002Fm², or ≥27 kg\u002Fm² with at least one additional cardiovascular risk factor (such as hypertension, diabetes and dyslipidemia). A total of 200 participants will be enrolled.\n\nParticipants are randomly assigned in a 1:1 ratio to either standard care or semaglutide (plus lifestyle advice) prior to their scheduled ablation. Semaglutide is administered according to the approved EU label with gradual dose escalation. All participants receive an implantable loop recorder (ILR) before ablation to continuously monitor heart rhythm throughout the study.\n\nThe primary objective is to determine whether semaglutide improves arrhythmia-free survival 12 months after AF ablation. Recurrence is defined as AF, atrial flutter, or atrial tachycardia lasting ≥30 seconds on continuous ILR monitoring, excluding the standard 3-month blanking period.\n\nSecondary outcomes include weight loss, changes in blood pressure, AF symptoms, quality of life, AF burden, need for repeat ablation, hospitalizations for cardiovascular causes, and changes in metabolic risk factors. The study also evaluates safety and tolerability of semaglutide in this patient population.\n\nThe study aims to determine whether targeted weight management with semaglutide before AF ablation can improve long-term rhythm outcomes and overall cardiovascular health. If successful, this strategy may offer a new approach to optimizing treatment and improving the results of catheter ablation for patients with AF and overweight or obesity",[354,27],"Atrial Fibrillation (AF)",[356,357,358,359],"Semaglutide","Implantable Loop Recorder","Ablation","Pulmonary Vein Isolation",{"date":245,"type":33},{"date":362,"type":33},"2026-03-23",{"date":364,"type":21},"2028-12-30",{"name":366,"class":39},"Emma Svennberg",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":261,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":378,"conditions":379,"keywords":387,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":400,"locationsCount":40},"100650884","long-term-effects-of-avocado-consumption-on-health-in-pre-diabetic-individuals-100650884","NCT07752225","Long-term Effects of Avocado Consumption on Health in Pre-diabetic Individuals","Effects of Long-term Avocado Consumption on Brain and Peripheral Cardiovascular Health in Pre-diabetic Individuals","Inclusion Criteria:\n\n* Men and women, aged between 40-75 years\n* Pre-diabetes: (A1C of 5.7%-6.4%, a fasting plasma glucose (FPG) of 100-125 mg\u002FdL, or a 2-hour oral glucose tolerance test (OGTT) result of 140-199 mg\u002FdL)\n* BMI ³ 25 kg\u002Fm2\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n\nExclusion Criteria:\n\n* Age less than 40 years old or older than 75 years\n* BMI \\\u003C 25 kg\u002Fm2\n* Type 1 or type 2 diabetes\n* habitual consumption of more than 1 avocado\u002F week\n* Left-handedness\n* Fasting serum total cholesterol \\> 8.0 mmol\u002FL\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use medication to treat blood pressure, lipid or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g. pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)\n* Blood donation in the 8 weeks before the start of the study\n* Difficulties to draw blood","75 Years",{"count":376,"type":21},34,[86],"Primary aim of the study is to assess the effect of 12-week daily avocado consumption on cerebral blood flow and markers of cardio- and vascular health in both, the periphery and the brain, in pre-diabetic individuals with overweight or obesity. Secondary objective is to assess the effects of 12-week daily avocado consumption on brain insulin sensitivity after intranasal insulin delivery, vascular function, markers of metabolic health, cognition, and psychological well-being. For that purpose a total of 34 men and women between the ages of 40-75 years old, will participate in a randomised crossover intervention study.",[380,381,382,383,384,385,386,27],"Prediabetes","Brain Insulin Sensitivity","Cerebral Blood Flow","Satiety and Food Intake","Food Reward","Brain Health","Vascular Function",[388,389,390,382,391,392,393,64,63,394,395],"Avocados","Brain insulin sensitivity","Brain vascular function","CBF","pCASL MRI","CANTAB","cognitive performance","brain health","2026-08-03",{"date":243,"type":33},{"date":70,"type":21},{"date":72,"type":21},{"name":401,"class":39},"Maastricht University Medical Center",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":418,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":40},"100650369","rosuvastatin-and-losartan-pharmacokinetics-after-bariatric-surgery-100650369","NCT07748273","Rosuvastatin and Losartan Pharmacokinetics After Bariatric Surgery","Comparative Evaluation of Rosuvastatin and Losartan Pharmacokinetics and the Associations Between Gut Microbiota Alterations and Changes in Systemic Drug Exposure in Patients Undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy","BARI-PK","Inclusion Criteria:\n\n* Adults aged 18 to 65 years;\n* Formal clinical indication for RYGB or sleeve gastrectomy after multidisciplinary assessment;\n* Bariatric surgery scheduled and no previous bariatric procedure;\n* Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Moderate or severe hepatic impairment, liver enzymes greater than 3 times the upper limit of normal, or Child-Pugh class B or C.\n* Estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m².\n* Concomitant use of drugs that substantially affect rosuvastatin pharmacokinetics and cannot be temporarily discontinued, including cyclosporine, gemfibrozil, or potent OATP1B1\u002FBCRP or CYP2C9 inhibitors.\n* Systemic antibiotic use within 3 months or probiotic, prebiotic, or synbiotic use within 4 weeks before sampling.\n* Continuous current rosuvastatin or other statin therapy unless medically discontinued with an adequate washout period under physician supervision.\n* Clinically relevant baseline hypotension, significant hyperkalemia, renal impairment, or another condition that makes a losartan test dose unsafe.\n* Severe postoperative complication preventing oral dosing, including active gastrointestinal leak, intractable vomiting, or severe anastomotic stenosis.\n* Pregnancy. Participants of childbearing potential undergo routine preoperative beta-hCG testing.","65 Years",{"count":181,"type":21},[86],"This prospective, open-label, non-randomized pharmacokinetic study will evaluate how Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy affect systemic exposure to single oral test doses of rosuvastatin and losartan. Sixty adults scheduled for bariatric surgery will enter one of two parallel groups according to the clinically selected operation (30 RYGB and 30 sleeve gastrectomy). Each participant will receive rosuvastatin 10 mg and losartan 25 mg once within 30 days before surgery and again approximately 12 weeks after surgery. Plasma samples collected before dosing and at 1.5 and 4 hours after dosing will be used with maximum a posteriori Bayesian estimation to estimate individual pharmacokinetic parameters. In the 30-participant RYGB group only, paired stool samples will be used to explore gut microbiota and untargeted fecal metabolomic changes. The primary objective is to compare within-participant changes and between-procedure differences in drug exposure after bariatric surgery.",[27,415,416,417],"Bariatric Surgery","Pharmacokinetics After Oral Intake","Drug Absorption",[419,420,421,422,423,424,425,426],"Roux-en-Y gastric bypass","sleeve gastrectomy","rosuvastatin","losartan","E-3174","gut microbiota","metabolomics","systemic exposure",{"date":428,"type":33},"2026-08-05",{"date":430,"type":21},"2026-08-02",{"date":432,"type":21},"2027-05-15",{"name":434,"class":39},"Hospital das Clínicas de Ribeirão Preto",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":48,"sex":17,"minAge":18,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":40},"100639487","growth-hormone-resistance-of-beta-cells-100639487","NCT07581860","Growth Hormone Resistance of Beta-cells","Growth Hormone Resistance of Beta-cells in People With Impaired Fasting Glucose vs Impaired Glucose Tolerance","GHRB-C","Inclusion Criteria:\n\n* body mass index \\>18.5kg\u002Fm2 and \\\u003C45.9kg\u002Fm2\n* impaired fasting glucose \\>\u002F= 100mg\u002FdL, \\\u003C\u002F= 126mg\u002FdL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg\u002FdL at two-hours)\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant during the study, or breastfeeding\n* current diagnosis or history of type 1 or type 2 diabetes\n* use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* history of bariatric surgery\n* known, uncontrolled hypothyroidism\n* history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* current cancer or cancer that has been in remission less than 5 years\n* first degree relative with type 1 diabetes\n* evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* greater than 3% weight loss within three months of screening or engaged in regular (\\>\u002F= 3 days per week), continuous moderate- or high-intensity exercise of \\>\u002F= 30 min duration\n* mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent","59 Years",{"count":20,"type":21},"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[447,27,448,449],"Healthy","Impaired Fasting Glucose (IFG)","Impaired Glucose Tolerance (Prediabetes)",{"date":307,"type":33},{"date":167,"type":21},{"date":453,"type":21},"2030-09-01",{"name":455,"class":39},"University of Missouri-Columbia",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":48,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":472,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":487},"100633670","evaluation-of-a-multicomponent-early-intervention-for-childhood-obesity-prevention-in-vulnerable-families-100633670","NCT07529704","Evaluation of a Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families","Evaluation of a Tailored Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families (Bambú Project): Randomized Controlled Trial With a Hybrid Type 1 Effectiveness-implementation Design","Bambú","Inclusion Criteria:\n\n* Mothers and\u002For fathers aged 18 years or older.\n* Primary caregivers of a healthy child aged 6 months to 3 years, born at term (≥37 weeks of gestation).\n* At least one parent with overweight or obesity (as defined by BMI criteria).\n* Families in a situation of vulnerability, defined as meeting ≥1 of the following criteria: (1) Low educational level of at least one parent (≤ lower secondary education or equivalent); (2) Precarious employment situation during the past year, (3) Perceived financial difficulties during the past year; (4) Insecure or unstable housing conditions; (5) Single-parent family or prolonged absence of one of the primary caregivers; (6) Recent immigration (≤10 years) without a stable support network or with language barriers.\n\nExclusion Criteria:\n\n* Parents of a child aged 6 months to 3 years with low birth weight (\\\u003C2500 g)\n* Parents of a child aged 6 months to 3 years from a multiple birth (e.g., twins, triplets)\n* Parents\u002Fcaregivers of a child aged 6 months to 3 years with congenital conditions, chronic diseases, or severe disabilities that may affect feeding, growth, or participation in the study\n* Parents or caregivers with severe physical or mental health conditions that would limit their ability to participate in the intervention or assessments\n* Families planning to move out of the study area during the study period",{"count":465,"type":21},526,[86],"Childhood obesity is a public health concern. Evidence-based, multicomponent, parenting interventions targeting early childhood and adapted to families' socioeconomic context are needed to prevent childhood obesity.\n\nThis study aims to evaluate the effectiveness of an early intervention in primary care for the prevention of childhood obesity, targeting vulnerable families where the mother and\u002For the father has overweight or obesity.\n\nMore specifically, the primary aim of this study is to evaluate the effectiveness the intervention to maintain a healthy weight in children aged 6 months to 3 years, measured by the BMI-for-age z-score at baseline, 6, 12, and 18 months, compared to usual care.\n\nThe study also aims to evaluate the effectiveness of the intervention, compared to usual care, for: promoting responsive feeding, improving dietary intake, improving parents' and children's physical activity levels, improving parents' eating styles, and improving children's sleep.\n\nFinally, the study aims to determine the feasibility of implementing the intervention, and to identify factors influencing change and contextual factors in the implementation process.\n\nA pragmatic cluster randomized controlled trial will be conducted. Approximately 526 families (parent-child family dyads) will be recruited, belonging to approximately 76 primary care centers. Primary care centers will be randomly assigned to either an intervention or control group.\n\nThe intervention has been previously co-designed with families and healthcare professionals, and consists of five weekly sessions and four monthly sessions, lasting two hours each. It will be delivered by previously trained healthcare professionals or by members of the research team, depending on the preferences and availability of the primary care center professionals. Approximately 38 intervention face-to-face groups will be conducted, one in each primary care center allocated to the intervention group.\n\nThe study will be conducted in Catalonia, Andalusia, the Balearic Islands and Castile and León (Spain).\n\nEffectiveness outcomes include child body mass index (BMI) z-score, parent feeding practices (measured with the Feeding Practices and Structure Questionnaire), child dietary intake (measured with the multiple-pass 24-hour recall), parents' eating behaviours (measured with the Dutch Eating Behavior Questionnaire), child movement (measured with the Movement Behavior Questionnaire), parents' movement behaviours (measured with the Brief Physical Activity Assessment Tool), and child sleep (measured with selected items from the Brief Infant Sleep Questionnaire).\n\nImplementation and feasibility outcomes will be assessed through interviews during and at the end of the intervention, and through attendance sheets and a final satisfaction questionnaire.\n\nThis study will provide pioneering insights into the implementation and effectiveness of this intervention within the public healthcare system in Spain. This will allow the potential implementation in the future at a larger scale.",[27,469,470,471],"Vulnerable Families","Children","Families With Infants",[473,474,475,476,477,478,479],"Pediatric obesity","Prevention","Vulnerable populations","Randomized controlled trial","Primary health care","Early intervention","Parenting interventions",{"date":428,"type":33},{"date":482,"type":33},"2026-03-02",{"date":484,"type":21},"2028-09",{"name":486,"class":39},"Helena Vall Roqué",4,{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":498,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":40},"100650682","effectiveness-of-a-low-calorie-diet-combined-with-intensive-lifestyle-intervention-using-integrated-personalized-diabetes-management-for-achieving-diabetes-remission-in-patients-with-type-2-diabetes-mellitus-100650682","NCT07748949","Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus","Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","REMIT-DM","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus with HbA1c level of 6.0 to 9.0%. Participants with HbA1c of 6.0 to 6.4% were required to be receiving oral glucose lowering medication.\n* Diagnosed with type 2 diabetes mellitus for less than 6 years.\n* Body mass index of 23 kg\u002Fm2 or greater.\n\nExclusion Criteria:\n\n* Receiving more than two oral glucose-lowering medications.\n* Receiving insulin therapy.\n* Use of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months before study enrollment.\n* Use of medications known to affect HbA1c within 3 months before study enrollment, including corticosteroids, vitamin C (excluding vitamin C obtained from natural dietary sources or fruits), vitamin E, trimethoprim-sulfamethoxazole, or hydroxyurea.\n* History of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the previous 6 months.\n* Unstable psychiatric disorders within the previous 2 years, including major depressive disorder, bipolar disorder, or schizophrenia.\n* Pregnant or breastfeeding women, or women planning to become pregnant within 12 months.\n* Presence of any of the following medical conditions based on medical history and clinical records, including chronic kidney disease with an estimated glomerular filtration rate less than 45 mL\u002Fmin\u002F1.73 m2, liver cirrhosis or hepatitis with alanine aminotransferase or aspartate aminotransferase more than 3 times the upper limit of normal, chronic alcohol abuse, hypothyroidism with thyroid-stimulating hormone more than 10 uIU\u002FmL, HIV infection, anemia (hemoglobin less than 10 g\u002FdL), iron deficiency, vitamin B12 deficiency, folate deficiency, thalassemia, glucose-6-phosphate dehydrogenase deficiency, hemolytic anemia, or hemoglobin more than 16 g\u002FdL, heart failure or ischemic heart disease within the previous 6 months.\n* History of blood donation or blood transfusion within the previous 3 months.\n* Uncontrolled diabetic retinopathy or other uncontrolled retinal disease, including maculopathy, based on medical records.\n* Signs, symptoms, or a history of malignancy within 5 years before screening, except for basal cell carcinoma, squamous cell carcinoma of the skin, or other carcinoma in situ.\n* Major surgery within 90 days before enrollment or planned major surgery within 6 months after enrollment.\n* No access to a smartphone capable of supporting the study application and internet-based data transmission.\n* Unable to maintain communication with the study investigators according to the study protocol.",{"count":497,"type":21},54,[86],"The goal of this clinical trial is to determine whether a low-calorie diet combined with intensive lifestyle intervention using Integrated Personalized Diabetes Management (iPDM) is more effective than standard care in achieving diabetes remission in adults with overweight and type 2 diabetes mellitus. The study will also evaluate the effects of the intervention on metabolic and clinical outcomes associated with diabetes remission.\n\nThe main questions it aims to answer are:\n\n* Does a low-calorie diet combined with intensive lifestyle intervention using iPDM increase the proportion of participants who achieve diabetes remission compared with standard care?\n* Does the intervention improve metabolic and patient-centered outcomes, including glycemic control, body weight, body composition, Time in Range (TIR) measured by continuous glucose monitoring (CGM), quality of life, and cost-effectiveness?\n\nResearchers will compare participants receiving a low-calorie diet combined with intensive lifestyle intervention using iPDM with participants receiving standard diabetes care to determine whether the intervention is more effective in achieving diabetes remission and improving metabolic health.\n\nParticipants will:\n\n* Be randomly assigned to either the intervention group or the standard care group.\n* Attend study visits for assessments of diabetes-related clinical and metabolic outcomes throughout the 6-month study.\n* If assigned to the intervention group, consume two low-calorie meal replacements per day and follow an individualized meal plan providing no more than 1,200 kcal per day during the first 3 months (intensive phase), together with a personalized exercise program, continuous glucose monitoring (CGM), and lifestyle counseling delivered via telemedicine every 2 weeks. During the following 3 months (maintenance phase), continue lifestyle modification with reinforcement sessions delivered via telemedicine every 4 weeks while following a meal plan providing no more than 1,500 kcal per day.",[57,27,501,502],"Remission","Lifestyle Intervention",[504,57,63,505],"Diabetes remission","Lifestyle intervention","2026-07-31",{"date":307,"type":33},{"date":509,"type":33},"2026-06-17",{"date":511,"type":21},"2027-07-31",{"name":513,"class":39},"Chulalongkorn University",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":261,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":40},"100650354","phase-2-glp-1-agonists-for-lung-function-improvement-and-muscle-restoration-in-copd-100650354","NCT07747805","GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD","Inclusion Criteria:\n\n* Age 40-80 years\n* Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁\u002FFVC \\\u003C 0.70\n* GOLD stage 1-3 COPD (FEV₁ \\>30% predicted)\n* Former smoker with a smoking history of at least 10 pack-years\n* Body mass index (BMI) ≥27 kg\u002Fm² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg\u002Fm²\n* Able and willing to provide written informed consent\n* Able to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\n* Type 2 diabetes mellitus (HbA1c \\> 6.5%)\n* Pregnancy or breastfeeding\n* Coagulopathy, defined as INR \\> 1.4 or platelet count \\\u003C80,000\u002FμL\n* Active malignancy, including lung cancer\n* Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral corticosteroids, tamoxifen, high-dose estrogen, testosterone)\n* Personal or family history of medullary thyroid carcinoma\n* Multiple endocrine neoplasia syndrome type 2 (MEN2)\n* Known hypersensitivity or contraindication to tirzepatide or its components\n* History of pancreatitis\n* Severe gastrointestinal disease that, in the opinion of the investigator, would increase risk from study participation\n* Significant diabetic retinopathy\n* Clinically significant renal impairment\n* Clinically significant gallbladder disease\n* Current treatment with a DPP-4 inhibitor\n* COPD exacerbation within 60 days prior to enrollment\n* Participation in pulmonary rehabilitation within 2 weeks prior to enrollment\n* Any medical, psychiatric, or social condition that, in the opinion of the investigators, may interfere with study participation, adherence to study procedures, or participant safety","80 Years",{"count":524,"type":21},30,[24],"Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation, obesity-related metabolic dysfunction, skeletal muscle impairment, and progressive decline in lung function. While obesity has historically been viewed as protective in COPD, emerging evidence suggests that excess adiposity and adipokine dysregulation, particularly elevated leptin levels, contribute to chronic inflammation, impaired muscle function, and worse clinical outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory, metabolic, and potential muscle-preserving effects beyond weight loss, making them promising therapeutic candidates for COPD.\n\nThe GLIMR COPD study is a prospective, randomized, controlled pilot trial designed to evaluate the effects of tirzepatide on lung function, skeletal muscle health, inflammation, and body composition in overweight and obese adults with COPD. Thirty participants will be enrolled at the Cleveland Clinic COPD Center, including 20 participants receiving tirzepatide and 10 age- and sex-matched control participants. Study participants will be followed for 12 months with assessments performed at screening, baseline, 6 months, and 12 months. Tirzepatide-treated participants will undergo standard dose escalation to a maintenance dose of 2.4 mg weekly.\n\nThe primary objective is to determine the effect of GLP-1 receptor agonist therapy on skeletal muscle function and physiology over 12 months. Secondary objectives include evaluating changes in body composition, systemic inflammation, adipokine signaling, immune function, pulmonary physiology, physical performance, and treatment tolerability.\n\nThe study is built around three mechanistic aims. First, we will characterize the effects of GLP-1 therapy on systemic inflammation and immune dysregulation using longitudinal blood-based proteomic analyses and adipokine measurements, including leptin and adiponectin. Second, we will investigate the impact of GLP-1 therapy on skeletal muscle mitochondrial function and fatty acid oxidation using muscle biopsies obtained at baseline and 12 months, combined with high-resolution respirometry, transcriptomics, metabolomics, and proteomics. Third, we will assess changes in clinical outcomes including lung function, body composition, muscle strength, and physical performance.\n\nParticipants will undergo comprehensive phenotyping that includes spirometry, respiratory muscle strength testing, six-minute walk testing, handgrip strength, sit-to-stand testing, body composition assessment, diaphragm ultrasound, and non-contrast CT imaging of the lungs and thighs. Blood samples will be collected for biomarker, proteomic, metabolomic, genomic, and immunologic analyses. Vastus lateralis muscle biopsies will be performed at baseline and study completion to evaluate mitochondrial bioenergetics and molecular pathways associated with muscle remodeling.\n\nEligible participants will be adults aged 40-80 years with COPD, a smoking history of at least 10 pack-years, and overweight or obesity. Individuals with diabetes, active malignancy, recent COPD exacerbations, contraindications to tirzepatide, or conditions that could interfere with study participation will be excluded.\n\nThis pilot study is designed to generate critical mechanistic and clinical data regarding the role of GLP-1 receptor agonists in COPD. Findings will help define the relationships among obesity, adipokine signaling, systemic inflammation, skeletal muscle dysfunction, and lung disease progression, while providing preliminary efficacy estimates to support the design of a future multicenter randomized clinical trial evaluating GLP-1 therapy as a novel treatment strategy for COPD.",[528,27,529],"COPD","Sarcopenia",[528,531,532],"sarcopenia","obesity",{"date":428,"type":33},{"date":535,"type":21},"2026-08-28",{"date":537,"type":21},"2029-08-15",{"name":539,"class":39},"The Cleveland Clinic",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":547,"maxAge":374,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":40},"100627305","optimizing-adaptive-intensive-behavioral-therapy-for-obesity-during-the-transition-to-older-adulthood-100627305","NCT07446907","Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood","Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood: A Sequential Multiple Assignment Randomized Trial","Inclusion Criteria:\n\n* Male or female sex\n* all racial and ethnic groups\n* BMI: 30-50 kg\u002Fm2\n* age 50-75 years\n* postmenopausal status for ≥1 y if female sex\n\nExclusion Criteria:\n\n* \\\u003C3 months stable use of other medications affecting body weight or appetite\n* \\>450 pounds (due to weight limitations of the DXA)\n* indication or previous diagnosis of sarcopenia\n* existing kidney disease\n* current binge eating disorder, anorexia, or bulimia\n* untreated hyper- or hypothyroidism, cancer (except basal cell), gastrointestinal disorders affecting food intake or nutrient absorption; any other medical condition, as determined by the study physician, precluding a HP diet and\u002For daily exercise","50 Years",{"count":549,"type":21},250,[86],"To test adaptive intensive behavioral therapy strategies comprising dietary patterns with varying amounts of protein and including supplemental protein or resistance exercise training for promoting weight loss and attenuating lean mass loss in adults aged 50-75 with obesity.",[27,529],[63,529],{"date":396,"type":33},{"date":191,"type":21},{"date":557,"type":21},"2031-06-30",{"name":559,"class":39},"University of Alabama at Birmingham",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":48,"sex":260,"minAge":18,"maxAge":567,"enrollmentInfo":568,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":40},"100650184","gestational-response-outcomes-and-weight-after-glp-1-use-100650184","NCT07743567","Gestational Response, Outcomes, and Weight After GLP-1 Use","GROW","Inclusion Criteria:\n\n* Adult women\n* Less than or equal to 20 weeks gestation at first visit\n* English speaking\n\nExclusion Criteria:\n\n* \\\u003C18 years at time of initial visit\n* Type 2 diabetes\n* History of bariatric surgery\n* Multiple gestation\n* Cannot consent for themselves\n* Cannot read and speak English\n* Incarcerated","45 Years",{"count":108,"type":21},"The goal of this observational study is to learn if using GLP-1RA medications for weight loss before pregnancy influences gestational weight gain and pregnancy outcomes. The main aims of the study are to:\n\n* Compare gestational weight gain between women with preconception GLP-1RA exposure and those without exposure.\n* Compare obstetrical outcomes between women with preconception GLP-1RA exposure and those without exposure.\n\nResearchers will compare pregnant women with a history of GLP-1RA use to pregnant women who have not used a GLP-1RA to compare differences.\n\nParticipants will be asked to complete questionnaires at multiple timepoints during and after pregnancy that ask questions about medication history, thoughts and feelings around food, etc.",[571,27,572],"Pregnant Individuals","Gestational Weight Gain",[574,575,576,577,578,579,580],"Glucagon-like peptide 1 receptor agonist","Pregnancy","Gestational weight gain","Maternal obesity","Pregnancy outcomes","Food noise","Preconception","2026-07-30",{"date":583,"type":33},"2026-08-04",{"date":585,"type":33},"2026-04-13",{"date":587,"type":21},"2028-04",{"name":589,"class":39},"University of Kansas Medical Center",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":22,"phases":599,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":4},"100649793","phase-3-evaluation-of-the-efficacy-and-safety-of-tirzepatide-a-dual-glp-1gip-agonist-on-functional-capacity-in-reduced-ejection-fraction-heart-failure-patients-with-obesity-100649793","NCT07738276","Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1\u002FGIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity","Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1\u002FGIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial","DUAL-HFrEF","Inclusion Criteria:\n\n* Age 18 years or older\n* Heart failure with reduced ejection fraction, defined as left ventricular ejection fraction ≤40% on echocardiography performed within the prior 3 months\n* Body mass index ≥27 kg\u002Fm², with at least one obesity-related comorbidity (hypertension, diabetes, or dyslipidemia)\n* Stable heart failure therapy for at least 4 weeks prior to enrollment, including beta-blockers, renin-angiotensin system inhibitors\u002Fangiotensin receptor-neprilysin inhibitors, and sodium-glucose cotransporter-2 inhibitors, if prescribed\n* Written informed consent\n\nExclusion Criteria:\n\n* Acute heart failure decompensation or cardiac hospitalization within the prior 4 weeks\n* Uncontrolled blood pressure (systolic blood pressure \\\u003C90 mmHg or ≥180 mmHg)\n* Advanced renal impairment (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment (liver enzymes elevated to 3 times the upper limit of normal)\n* Active pancreatitis\n* Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2\n* Pregnancy or breastfeeding\n* Known hypersensitivity to glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonist drugs\n* Concurrent use of other weight-loss medications",{"count":181,"type":21},[600],"PHASE3","The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide. The main questions it aims to answer are:\n\nDoes tirzepatide improve how far participants can walk in 6 minutes? Does tirzepatide improve heart failure symptoms and quality of life? What side effects do participants have when taking tirzepatide?\n\nResearchers will compare tirzepatide to a placebo (a look-alike substance that contains no drug) to see if tirzepatide improves physical function in people with heart failure and obesity.\n\nParticipants will:\n\nGet a weekly injection of tirzepatide or a placebo under the skin for 6 months Start at a low dose, which may be raised slowly based on how well they tolerate it Keep taking their usual heart failure medicines Visit the clinic for checkups, blood tests, heart ultrasounds, and a 6-minute walk test Answer questions about their quality of life and heart failure symptoms",[603,27,604],"Heart Failure and Reduced Ejection Fraction","Tirzepatide",[604,606,607,63,608,609,610,476],"GLP-1\u002FGIP receptor agonist","Heart failure with reduced ejection fraction","6-minute walk test","Weight loss","Functional capacity",{"date":396,"type":33},{"date":613,"type":21},"2026-07-18",{"date":615,"type":21},"2027-12-22",{"name":617,"class":39},"Shahid Beheshti University of Medical Sciences",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":632,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":641,"startDateStruct":642,"completionDateStruct":643,"leadSponsor":645,"locationsCount":40},"100648967","transit-bipartition-after-sleeve-gastrectomy-100648967","NCT07728682","Transit Bipartition After Sleeve Gastrectomy","Clinical, Metabolic, and Physiological Evaluation of Conversion From Sleeve Gastrectomy to Intestinal Transit Bipartition","BTT-SLEEVE","Inclusion Criteria:\n\n* Age 18 years or older;\n* Previous sleeve gastrectomy for the treatment of obesity;\n* Follow-up at the HCRP gastrosurgery\u002Fbariatric surgery outpatient clinic through 2026;\n* Clinical evaluation supporting revisional conversion to intestinal transit bipartition;\n* Willingness to undergo the new surgical procedure and provide written informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis;\n* Absence of willingness to undergo a new surgical procedure.",{"count":84,"type":21},[86],"This prospective, single-center study will evaluate adults undergoing revisional conversion from sleeve gastrectomy to intestinal transit bipartition. Forty participants will complete clinical, endoscopic, physiological, metabolic, hormonal, imaging, and stool assessments before surgery and during follow-up. The primary outcome is the within-participant change in solid-meal gastric emptying half-time (T½), measured by standardized scintigraphy from baseline to 6 months. Secondary and exploratory outcomes include reflux symptoms, DeMeester score and acid exposure, route-specific gastric transit, GLP-1 and ghrelin responses, glucose metabolism, fecal elastase, gut microbiota, body-weight trajectory, comorbidities, gastroileal anastomotic caliber, and safety.",[27,630,631,415],"Gastroesophageal Reflux (GERD)","Weight Recurrence",[420,633,634,635,636,637,638,639,640],"transit bipartition","gastric emptying","scintyigraphy","T1\u002F2","DeMeester score","gastroileal anastomosis","GLP-1","fecal elastase",{"date":396,"type":33},{"date":430,"type":21},{"date":644,"type":21},"2027-09-30",{"name":434,"class":39},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":547,"enrollmentInfo":653,"targetDuration":4,"studyType":22,"phases":655,"briefSummary":656,"conditions":657,"keywords":658,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":664,"leadSponsor":666,"locationsCount":40},"100640527","transcutaneous-auricular-vagus-nerve-stimulation-for-poor-weight-loss-response-to-incretin-receptor-agonists-100640527","NCT07619989","Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists","Adjunctive Transcutaneous Auricular Vagus Nerve Stimulation in Overweight or Obese Patients With a Suboptimal Weight-Loss Response to Incretin Receptor Agonists: A Single-Center, Randomized, Sham-Controlled Study","Inclusion Criteria:\n\n1. Individuals with obesity, or overweight accompanied by at least one weight-related comorbidity (e.g., hypertension or fatty liver disease), who have been receiving tirzepatide therapy for at least 12 weeks and have achieved ≤10% weight loss during treatment;\n2. Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of diseases that may substantially affect body weight homeostasis, including Cushing's syndrome, uncontrolled thyroid disease (thyroid-stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL), malignancy, or similar conditions;\n2. Use within the past 3 months of medications, other than incretin receptor agonists, that may significantly affect body weight, including glucocorticoids and antipsychotic agents;\n3. Skin infection or damage involving the auricular area;\n4. Women planning pregnancy in the near future;\n5. Contraindications to MRI, such as metallic prostheses or claustrophobia;\n6. Diagnosis of diabetes mellitus; Inability to complete the 12-week intervention period for practical reasons, such as frequent business travel or planned travel.",{"count":654,"type":21},24,[86],"This is a single-center, randomized, participant-blinded, sham-controlled trial designed to evaluate the adjunctive effect of transcutaneous auricular vagus nerve stimulation (taVNS) in overweight or obese patients who show a suboptimal weight-loss response to incretin receptor agonist therapy. A total of 24 participants will be randomly assigned to receive either taVNS plus tirzepatide 5 mg or sham stimulation plus tirzepatide 5 mg for 12 weeks. The primary objective is to compare the percent change in body weight from baseline to week 12 between the two groups.",[27],[27,659,660,661],"Transcutaneous Auricular Vagus Nerve Stimulation","Incretin Receptor Agonists","Non-responders",{"date":506,"type":33},{"date":167,"type":21},{"date":665,"type":21},"2027-09-01",{"name":667,"class":39},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":48,"sex":260,"minAge":547,"maxAge":410,"enrollmentInfo":675,"targetDuration":4,"studyType":22,"phases":676,"briefSummary":677,"conditions":678,"keywords":681,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":691,"completionDateStruct":692,"leadSponsor":694,"locationsCount":40},"100647115","effect-of-whole-or-skimmed-milk-greek-yogurt-on-integrated-muscle-protein-synthesis-glucose-homeostasis-and-cognition-in-post-menopausal-women-100647115","NCT07705724","Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, and Cognition in Post-Menopausal Women","Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, And Cognition in Post-Menopausal Women","Inclusion Criteria:\n\n1. Aged 50 to 65 years\n2. Body mass index ≥25 to \\\u003C40 kg\u002Fm2 or body fat ≥36%\n3. Able to provide informed consent\n4. Absence of menstruation for ≥12 months without the use of hormonal contraceptives, or one of the following:\n\n   * Another medical cause of menopause e.g., history of bilateral oophorectomy\n   * Clinician-confirmed menopausal status for those with hysterectomy and retained\u002Funknown ovaries\n   * Partial\u002Ftotal hysterectomy ≥12 months ago and current age ≥55 years\n\nExclusion Criteria:\n\n1. Allergy or intolerance to dairy products (other allergies or intolerances may be excluded if they are not compatible with the study meals and how they are prepared)\n2. Conditions, medications, or recent changes in medications that cause participants to be metabolically unstable (e.g., renal, cardiovascular, thyroid, polycystic ovary syndrome, type-1 and type-2 diabetes)\n3. Gastric bypass\u002Fbariatric surgery in the previous 5 years\n4. Pregnancy or nursing in the prior 12 months\n5. Weight loss or gain \\>5 kg in the last two months\n6. Unable or unwilling to suspend use of blood thinning medications and non-steroidal anti-inflammatory drugs for the duration of the study\n7. Unwilling to abstain from vigorous exercise for the study period\n8. Does not or will not eat all foods on the standardized diet (e.g., allergies, intolerances, or taste preferences)\n9. Participants may be excluded at the Principal Investigator's discretion if their health or body composition is not compatible with the required study procedures",{"count":84,"type":21},[86],"The study will examine the impact of adding two servings per day of skimmed or whole milk Greek yogurt on integrated muscle protein synthesis (iMPS), blood sugar control, and cognition in post-menopausal women with overweight and obesity.",[27,679,680],"Women","Menopause",[682,683,684,685,686,679,687,688],"Muscle Protein Synthesis","Protein Turnover","Glycemic Control","Cognition","Post-Menopause","Protein","Dairy","2026-07-29",{"date":581,"type":33},{"date":247,"type":21},{"date":693,"type":21},"2029-04-01",{"name":695,"class":39},"University of Arkansas"]